Matinas BioPharma (MTNB) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $53.8M

Matinas BioPharma (NYSE: MTNB) reported Q3 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02).

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
• SAS CEO van der Werff emerges as frontrunner for Air Canada top job - Bloomberg